|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2014
gptkb:Oncology
gptkb:pancreatic_cancer
ovarian cancer
|
|
gptkbp:chemical_formula
|
C24 H23 N3 O4
|
|
gptkbp:clinical_trial
|
Phase III
NCT01844986
NCT02000622
NCT02855944
NCT02184195
NCT02834013
|
|
gptkbp:clinical_use
|
maintenance therapy
treatment of advanced cancer
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:emaapproval_date
|
March 2015
|
|
gptkbp:healthcare
|
December 19, 2014
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lynparza
|
|
gptkbp:indication
|
gptkb:HER2-negative_breast_cancer
metastatic breast cancer
BRCA-mutated pancreatic cancer
recurrent ovarian cancer
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_compared_to
|
chemotherapy
placebo
other PARP inhibitors
|
|
gptkbp:marketed_as
|
gptkb:Olaparib
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
PARP inhibitor
|
|
gptkbp:research_areas
|
oncology
personalized medicine
pharmacogenomics
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
abdominal pain
vomiting
diarrhea
insomnia
constipation
loss of appetite
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:BRCA2
gptkb:BRCA1
|
|
gptkbp:weight
|
393.46 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca
|
|
gptkbp:bfsLayer
|
4
|